1-10 of 10
John D. Roberts
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

Beata Holkova, Adriana Zingone, Maciej Kmieciak, Prithviraj Bose, Ashraf Z. Badros, Peter M. Voorhees, Rachid Baz, Neha Korde, Hui-Yi Lin, Jin-Qiu Chen, Michelle Herrmann, Liqiang Xi, Mark Raffeld, Xiuhua Zhao, Wen Wan, Mary Beth Tombes, Ellen Shrader, Caryn Weir-Wiggins, Heidi Sankala, Kevin T. Hogan, Austin Doyle, Christina M. Annunziata, Martha Wellons, John D. Roberts, Daniel Sullivan, Ola Landgren, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (5): 1067–1075.
https://doi.org/10.1158/1078-0432.CCR-15-1076
Published: 29 February 2016
View article titled, A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma
Open the PDF for A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms

Beata Holkova, Maciej Kmieciak, E. Brent Perkins, Prithviraj Bose, Rachid C. Baz, G. David Roodman, Robert K. Stuart, Viswanathan Ramakrishnan, Wen Wan, Cody J. Peer, Jana Dawson, Loveleen Kang, Connie Honeycutt, Mary Beth Tombes, Ellen Shrader, Caryn Weir-Wiggins, Martha Wellons, Heidi Sankala, Kevin T. Hogan, A. Dimitrios Colevas, L. Austin Doyle, William D. Figg, Domenico Coppola, John D. Roberts, Daniel Sullivan, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5652–5662.
https://doi.org/10.1158/1078-0432.CCR-14-0805
Published: 13 November 2014
View article titled, Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms
Open the PDF for Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms in another window
Includes: Supplementary data
Journal Articles

Phase II trials powered to detect tumor subsets through the application of predictive markers.

John D. Roberts, V. Ramakrishnan
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19_Supplement): B44.
Published: 15 August 2014
View article titled, Phase II trials powered to detect tumor subsets through the application of predictive markers.
Journal Articles

A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2

Beata Holkova, Jeffrey G. Supko, Matthew M. Ames, Joel M. Reid, Geoffrey I. Shapiro, Edward Brent Perkins, Viswanathan Ramakrishnan, Mary Beth Tombes, Connie Honeycutt, Renee M. McGovern, Maciej Kmieciak, Ellen Shrader, Martha D. Wellons, Heidi Sankala, Austin Doyle, John Wright, John D. Roberts, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1873–1883.
https://doi.org/10.1158/1078-0432.CCR-12-2926
Published: 02 April 2013
View article titled, A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
Open the PDF for A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2 in another window
Includes: Supplementary data
Journal Articles

Phase II Trials Powered to Detect Tumor Subtypes

John D. Roberts, Viswanathan Ramakrishnan
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (17): 5538–5545.
https://doi.org/10.1158/1078-0432.CCR-10-2466
Published: 01 September 2011
View article titled, Phase II Trials Powered to Detect Tumor Subtypes
Open the PDF for Phase II Trials Powered to Detect Tumor Subtypes in another window
Journal Articles

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms

Beata Holkova, E. Brent Perkins, Viswanathan Ramakrishnan, Mary Beth Tombes, Ellen Shrader, Neha Talreja, Martha D. Wellons, Kevin T. Hogan, G. David Roodman, Domenico Coppola, Loveleen Kang, Jana Dawson, Robert K. Stuart, Cody Peer, William D. Figg, Sr., Sarah Kolla, Austin Doyle, John Wright, Daniel M. Sullivan, John D. Roberts, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (10): 3388–3397.
https://doi.org/10.1158/1078-0432.CCR-10-2876
Published: 15 May 2011
View article titled, Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms
Open the PDF for Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms in another window
Includes: Supplementary data
Journal Articles

Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation

Guo Zhang, Margaret A. Park, Clint Mitchell, Hossein Hamed, Mohamed Rahmani, Aditi Pandya Martin, David T. Curiel, Adly Yacoub, Martin Graf, Ray Lee, John D. Roberts, Paul B. Fisher, Steven Grant, Paul Dent
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (17): 5385–5399.
https://doi.org/10.1158/1078-0432.CCR-08-0469
Published: 02 September 2008
View article titled, Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation
Open the PDF for Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma

John D. Roberts, Mitchell R. Smith, Eric J. Feldman, Louise Cragg, Michael M. Millenson, Gail J. Roboz, Connie Honeycutt, Rose Thune, Kristin Padavic-Shaller, W. Hans Carter, Viswanathan Ramakrishnan, Anthony J. Murgo, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19): 5809–5816.
https://doi.org/10.1158/1078-0432.CCR-05-2730
Published: 04 October 2006
View article titled, Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma
Open the PDF for Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma in another window
Journal Articles

Pharmacokinetic and Pharmacodynamic Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitor AG2034

Howard L. McLeod, James Cassidy, Robert H. Powrie, David G. Priest, Mark A. Zorbas, Timothy W. Synold, Stephen Shibata, Darcy Spicer, Donald Bissett, Yazdi K. Pithavala, Mary A. Collier, Linda J. Paradiso, John D. Roberts
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (7): 2677–2684.
Published: 01 July 2000
View article titled, Pharmacokinetic and Pharmacodynamic Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitor AG2034
Open the PDF for Pharmacokinetic and Pharmacodynamic Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitor AG2034 in another window
Journal Articles

A Multicenter Phase II Trial of Losoxantrone (DuP-941) in Hormone-refractory Metastatic Prostate Cancer

Susan D. Huan, Ronald B. Natale, David J. Stewart, George P. Sartiano, Philip J. Stella, John D. Roberts, Aston L. Symes, Michael Finizio
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (4): 1333–1336.
Published: 01 April 2000
View article titled, A Multicenter Phase II Trial of Losoxantrone (DuP-941) in Hormone-refractory Metastatic Prostate Cancer
Open the PDF for A Multicenter Phase II Trial of Losoxantrone (DuP-941) in Hormone-refractory Metastatic Prostate Cancer in another window